Roivant Sciences Ltd.
ROIV
Classifica tra le azioni
#978
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company... Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.
Prezzo delle azioni
$33.73
Ultima sincronizzazione: 2026-07-31
Capitalizzazione di mercato
$24.37B
Variazione (1 giorno)
-2.28%
Variazione (1 anno)
90.15%
Paese
GB
Scambia Roivant Sciences Ltd. (ROIV)
Categoria
Healthcare
Rapporto P/S per Roivant Sciences Ltd. (ROIV)
Rapporto P/S al October 2026 TTM: 3.22K
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Roivant Sciences Ltd., il rapporto P/S attuale (TTM) è 3.22K. Alla fine del 2024, era pari a 65.46.
Storico del rapporto P/S per Roivant Sciences Ltd. da 2020 a 2026
Rapporto P/S alla fine di ogni anno
| Anno | Rapporto P/S | Cambia |
|---|---|---|
| 2026 (TTM) | 3.22K | 1,179.79% |
| 2025 | 251.93 | 284.85% |
| 2024 | 65.46 | -23.74% |
| 2023 | 85.84 | 43.44% |
| 2022 | 59.84 | -78.74% |
| 2021 | 281.46 | 167.51% |
| 2020 | 105.21 | 0.00% |
Rapporto P/S per aziende simili o concorrenti
| Azienda | Rapporto P/S | Differenza del rapporto P/S | Il paese |
|---|---|---|---|
| 10.02 | -99.69% |
US
|
|
| 40.55 | -98.74% |
US
|
|
| 3.96 | -99.88% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | -99.69% |
NL
|
